Normal somatomedin-C-insulin-like growth factor I binding and action in cultured human fibroblasts from Turner syndrome

Ronald (Ron) Rosenfeld, L. A. Dollar, R. L. Hintz, C. Conover

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Growth retardation is a major manifestation of Turner syndrome (TS). Since plasma growth hormone and somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) levels are generally normal, growth failure has been ascribed to peripheral defects in SM-C/IGF-I receptors or action. We have measured the binding of [125I]SM-C/IGF-I to cultured fibroblast monolayers derived from patients with Turner syndrome and have evaluated SM-C/IGF-I stimulation of both [3H]thymidine incorporation and cell replication. When compared to fibroblasts from normal adults, newborns, and age-matched children, no significant differences were observed in specific binding of [125I]SM-C/IGF-I to fibroblast monolayers, and displacement curves demonstrated similar receptor affinities for all groups. Similarly, equivalent SM-C/IGF-I stimulation of [3H]thymidine incorporation was seen in both Turner and control fibroblasts. In the absence of serum SM-C/IGF-I, at a concentration of 10-25 ng/ml, stimulated thymidine incorporation 3.7-11.8-fold in Turner fibroblasts and 1.9-9.8-fold in control cells. In conbination with 1.0% human hypopituitary serum (HHS), SM-C/IGF-I stimulated thymidine incorporation 20-70-fold in all cell lines. Cell replication in both TS and control cells was increased 90% by the combination of SM-C/IGF-I + 0.05% HHS, and 140% by SM-C/IGF-I + 0.5% HHS + dexamethasone. We conclude that TS fibroblasts have normal SM-C/IGF-I receptors and sensitivity, and are capable of enhanced DNA synthesis and replication following SM-C/IGF-I stimulation.

Original languageEnglish (US)
Pages (from-to)502-509
Number of pages8
JournalActa Endocrinologica
Volume104
Issue number4
StatePublished - 1983
Externally publishedYes

Fingerprint

Turner Syndrome
Insulin-Like Growth Factor I
Fibroblasts
Thymidine
IGF Type 1 Receptor
Serum
Growth
DNA Replication
Dexamethasone
Growth Hormone

ASJC Scopus subject areas

  • Endocrinology

Cite this

Normal somatomedin-C-insulin-like growth factor I binding and action in cultured human fibroblasts from Turner syndrome. / Rosenfeld, Ronald (Ron); Dollar, L. A.; Hintz, R. L.; Conover, C.

In: Acta Endocrinologica, Vol. 104, No. 4, 1983, p. 502-509.

Research output: Contribution to journalArticle

Rosenfeld, Ronald (Ron) ; Dollar, L. A. ; Hintz, R. L. ; Conover, C. / Normal somatomedin-C-insulin-like growth factor I binding and action in cultured human fibroblasts from Turner syndrome. In: Acta Endocrinologica. 1983 ; Vol. 104, No. 4. pp. 502-509.
@article{54f75e7801df4faa886eb97013c28e51,
title = "Normal somatomedin-C-insulin-like growth factor I binding and action in cultured human fibroblasts from Turner syndrome",
abstract = "Growth retardation is a major manifestation of Turner syndrome (TS). Since plasma growth hormone and somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) levels are generally normal, growth failure has been ascribed to peripheral defects in SM-C/IGF-I receptors or action. We have measured the binding of [125I]SM-C/IGF-I to cultured fibroblast monolayers derived from patients with Turner syndrome and have evaluated SM-C/IGF-I stimulation of both [3H]thymidine incorporation and cell replication. When compared to fibroblasts from normal adults, newborns, and age-matched children, no significant differences were observed in specific binding of [125I]SM-C/IGF-I to fibroblast monolayers, and displacement curves demonstrated similar receptor affinities for all groups. Similarly, equivalent SM-C/IGF-I stimulation of [3H]thymidine incorporation was seen in both Turner and control fibroblasts. In the absence of serum SM-C/IGF-I, at a concentration of 10-25 ng/ml, stimulated thymidine incorporation 3.7-11.8-fold in Turner fibroblasts and 1.9-9.8-fold in control cells. In conbination with 1.0{\%} human hypopituitary serum (HHS), SM-C/IGF-I stimulated thymidine incorporation 20-70-fold in all cell lines. Cell replication in both TS and control cells was increased 90{\%} by the combination of SM-C/IGF-I + 0.05{\%} HHS, and 140{\%} by SM-C/IGF-I + 0.5{\%} HHS + dexamethasone. We conclude that TS fibroblasts have normal SM-C/IGF-I receptors and sensitivity, and are capable of enhanced DNA synthesis and replication following SM-C/IGF-I stimulation.",
author = "Rosenfeld, {Ronald (Ron)} and Dollar, {L. A.} and Hintz, {R. L.} and C. Conover",
year = "1983",
language = "English (US)",
volume = "104",
pages = "502--509",
journal = "Acta Endocrinology",
issn = "0001-5598",
publisher = "Munksgaard International Publishers",
number = "4",

}

TY - JOUR

T1 - Normal somatomedin-C-insulin-like growth factor I binding and action in cultured human fibroblasts from Turner syndrome

AU - Rosenfeld, Ronald (Ron)

AU - Dollar, L. A.

AU - Hintz, R. L.

AU - Conover, C.

PY - 1983

Y1 - 1983

N2 - Growth retardation is a major manifestation of Turner syndrome (TS). Since plasma growth hormone and somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) levels are generally normal, growth failure has been ascribed to peripheral defects in SM-C/IGF-I receptors or action. We have measured the binding of [125I]SM-C/IGF-I to cultured fibroblast monolayers derived from patients with Turner syndrome and have evaluated SM-C/IGF-I stimulation of both [3H]thymidine incorporation and cell replication. When compared to fibroblasts from normal adults, newborns, and age-matched children, no significant differences were observed in specific binding of [125I]SM-C/IGF-I to fibroblast monolayers, and displacement curves demonstrated similar receptor affinities for all groups. Similarly, equivalent SM-C/IGF-I stimulation of [3H]thymidine incorporation was seen in both Turner and control fibroblasts. In the absence of serum SM-C/IGF-I, at a concentration of 10-25 ng/ml, stimulated thymidine incorporation 3.7-11.8-fold in Turner fibroblasts and 1.9-9.8-fold in control cells. In conbination with 1.0% human hypopituitary serum (HHS), SM-C/IGF-I stimulated thymidine incorporation 20-70-fold in all cell lines. Cell replication in both TS and control cells was increased 90% by the combination of SM-C/IGF-I + 0.05% HHS, and 140% by SM-C/IGF-I + 0.5% HHS + dexamethasone. We conclude that TS fibroblasts have normal SM-C/IGF-I receptors and sensitivity, and are capable of enhanced DNA synthesis and replication following SM-C/IGF-I stimulation.

AB - Growth retardation is a major manifestation of Turner syndrome (TS). Since plasma growth hormone and somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) levels are generally normal, growth failure has been ascribed to peripheral defects in SM-C/IGF-I receptors or action. We have measured the binding of [125I]SM-C/IGF-I to cultured fibroblast monolayers derived from patients with Turner syndrome and have evaluated SM-C/IGF-I stimulation of both [3H]thymidine incorporation and cell replication. When compared to fibroblasts from normal adults, newborns, and age-matched children, no significant differences were observed in specific binding of [125I]SM-C/IGF-I to fibroblast monolayers, and displacement curves demonstrated similar receptor affinities for all groups. Similarly, equivalent SM-C/IGF-I stimulation of [3H]thymidine incorporation was seen in both Turner and control fibroblasts. In the absence of serum SM-C/IGF-I, at a concentration of 10-25 ng/ml, stimulated thymidine incorporation 3.7-11.8-fold in Turner fibroblasts and 1.9-9.8-fold in control cells. In conbination with 1.0% human hypopituitary serum (HHS), SM-C/IGF-I stimulated thymidine incorporation 20-70-fold in all cell lines. Cell replication in both TS and control cells was increased 90% by the combination of SM-C/IGF-I + 0.05% HHS, and 140% by SM-C/IGF-I + 0.5% HHS + dexamethasone. We conclude that TS fibroblasts have normal SM-C/IGF-I receptors and sensitivity, and are capable of enhanced DNA synthesis and replication following SM-C/IGF-I stimulation.

UR - http://www.scopus.com/inward/record.url?scp=0021038390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021038390&partnerID=8YFLogxK

M3 - Article

C2 - 6362310

AN - SCOPUS:0021038390

VL - 104

SP - 502

EP - 509

JO - Acta Endocrinology

JF - Acta Endocrinology

SN - 0001-5598

IS - 4

ER -